Skip to content

Author

Xiao-Ya Li

We have 5 of 13 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Lipoprotein(a) and Plaque Vulnerability: Mechanistic Insights, Imaging Evidence, and Clinical Implications

Although low-density lipoprotein cholesterol (LDL-C) can now be effectively reduced, substantial residual risk of acute ischemic cardiovascular events persists. Lipoprotein(a) [Lp(a)] is an established causal risk factor for atherosclerotic cardiovascular disease (ASCVD), yet its mechanistic links to plaque vulnerabili...

Quan-Hao Sun, Ya-Jie Wang, Xiao-Ya Li et al. · 0 citations
Meta-analysis Open access Sep 2026

Dose-response and time-course effects of ecnoglutide in type 2 diabetes: a systematic review and meta-analysis of efficacy

Dose-response analysis showed that ecnoglutide exhibited a clear dose-dependent relationship for HbA1c, FPG, and body weight at doses ranging from 0.4 to 1.2 mg, while PPG was less affected by dose.

Yi-Xuan Feng, Chang-Xin Sun, Xiao-Ya Li et al. · 0 citations
Review Open access Sep 2026

Apolipoprotein B in cardiovascular risk assessment: beyond traditional lipid markers

Apolipoprotein B (ApoB) serves as the structural backbone of triglyceride (TG)-rich lipoproteins and low-density lipoprotein (LDL) particles and plays a key role in lipid transport. A growing body of evidence indicates that circulating ApoB levels are closely associated with the development of cardiovascular diseases s...

Ling-Ling Li, Yi-Xuan Feng, Xiao-Ya Li et al. · 0 citations
Review Open access Sep 2026

Polydatin Delivery Systems and Nanomedicine: Pharmacology, Preclinical Evidence, and Translation

Background: Polydatin has shown anti-inflammatory, antioxidant, and cytoprotective effects in preclinical studies. Its development is limited by low oral bioavailability, extensive metabolism, and poorly defined tissue exposure. Objectives: This review summarizes the pharmacology and delivery systems of polydatin, dist...

Xiao-Ya Li, Ling-Ling Li, Yong-Fang Yuan et al. · 0 citations
Open access Aug 2026

Polydatin in combination with hawthorn flavonoids alleviates atherosclerosis by inhibiting mitochondrial division through the YTHDF2-DRP1 axis.

PH exerts a protective effect on HUVECs and prevents AS by regulating the YTHDF2/DRP1 axis to restore mitochondrial homeostasis, thereby providing a novel therapeutic approach for AS.

Yu-Juan Li, Xiao-Nan Zhang, Sheng-Jie Yang et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.